byKing's College London

Almost half of the world’s population lives in places where mosquito-borne dengue can break out. The Aedes mosquito is a known carrier. Credit: Pixabay/CC0 Public Domain

The first global standard that harmonizes what outcomes to measure in dengue treatment trials has beenpublishedOct. 7 inThe Lancet Infectious Diseases. Co-led by researchers at King's and the University of Oxford, this solves a longstanding discrepancy in terms of what is measured in these trials.

The project was undertaken as a part of the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) program.

About half the world's population is at risk ofdengueinfection. In-country transmission of dengue has doubled in Europe over the past year, with the ECDC reporting a historic peak of 304 locally acquired cases in 2024. There has also been a rise in dengue cases globally driven by the acceleration of the climate crisis.

Dengue is a viral infection and is the most rapidly spreading mosquito-borne viral disease worldwide. Its increase globally is driven by climate change, urbanization, human mobility and the expanding range of Aedes mosquitoes. There are currently no specific treatments for patients with dengue.

Despite growing research interest, outcomes and measurements have been assessed differently across a variety of trials, which limits how the evidence from these can be compared and synthesized.

A new global standard enables faster, more comparable evaluations for regulators and guidelines and could help accelerate a path to finding a treatment for dengue fever, as well as improve future clinical guidelines development.

The paper published inThe Lancet Infectious Diseaseshad contributors from 36 countries and actively included people with lived experience ofdengue fever. This means the outcome scale is reflective of their experiences and need, while also balancing these with clinical needs.

"With dengue spreading rapidly across continents, we urgently need new treatments. This global standard provides the clarity regulators and researchers require to evaluate therapies faster and make them more widely accessible," says Daniel Munblit, corresponding author on the paper, reader in pediatrics, King's College London.

"Bringing together aglobal consensuson clinically relevant outcomes to be measured in all future dengue clinical trials, is a major step forward for the dengue therapeutics field," says Sophie Yacoub, corresponding author on the paper, associate professor, University of Oxford.

"Harmonizing outcomes across dengue trials strengthens both the quality of each study and the scientific value of the data generated. Initiatives like this support the World Health Organization's efforts to advanceclinical trialsglobally, ensuring robust evidence for health interventions," says Laura Merson, Head of Data, International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) and Head of Clinical Research, Institut Pasteur de Dakar.

More information: Sophie Yacoub et al, Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE), The Lancet Infectious Diseases (2025). DOI: 10.1016/S1473-3099(25)00500-6 www.thelancet.com/journals/lan … (25)00500-6/abstract Journal information: Lancet Infectious Diseases

Provided by King's College London